Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Myovant Sciences nets $202mm in IPO on NYSE

Executive Summary

Just four months after its inception, start-up Myovant Sciences Ltd. (men’s and women’s health therapeutics) netted $202mm in an initial public offering of 14.5mm shares at $15, the high end of its anticipated range, and up-sized from its original 13mm shares. This marks the largest biotech IPO so far this year.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies